CN111471560A - 一种茶黄素保健酒及其制备方法 - Google Patents
一种茶黄素保健酒及其制备方法 Download PDFInfo
- Publication number
- CN111471560A CN111471560A CN202010198261.4A CN202010198261A CN111471560A CN 111471560 A CN111471560 A CN 111471560A CN 202010198261 A CN202010198261 A CN 202010198261A CN 111471560 A CN111471560 A CN 111471560A
- Authority
- CN
- China
- Prior art keywords
- parts
- wine
- theaflavin
- tea
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014101 wine Nutrition 0.000 title claims abstract description 72
- 230000036541 health Effects 0.000 title claims abstract description 47
- 235000014620 theaflavin Nutrition 0.000 title claims abstract description 41
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 title claims abstract description 40
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 title claims abstract description 40
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 title claims abstract description 40
- 229940026509 theaflavin Drugs 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 244000269722 Thea sinensis Species 0.000 claims abstract description 73
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 11
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 9
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 9
- 240000000249 Morus alba Species 0.000 claims abstract description 9
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 9
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 9
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 9
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 9
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 8
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 8
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 8
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 8
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 8
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 8
- 235000012907 honey Nutrition 0.000 claims abstract description 8
- 238000002791 soaking Methods 0.000 claims abstract description 8
- 241001633680 Polygonatum odoratum Species 0.000 claims abstract description 7
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 3
- 235000013616 tea Nutrition 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- 239000000243 solution Substances 0.000 claims description 52
- 239000012528 membrane Substances 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 16
- 235000013824 polyphenols Nutrition 0.000 claims description 16
- 239000008213 purified water Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 102000030523 Catechol oxidase Human genes 0.000 claims description 12
- 108010031396 Catechol oxidase Proteins 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000012266 salt solution Substances 0.000 claims description 10
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000011343 solid material Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 235000009569 green tea Nutrition 0.000 claims description 5
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000012466 permeate Substances 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 238000001223 reverse osmosis Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 44
- 210000004369 blood Anatomy 0.000 abstract description 43
- 230000036772 blood pressure Effects 0.000 abstract description 23
- 210000004185 liver Anatomy 0.000 abstract description 23
- 230000006870 function Effects 0.000 abstract description 13
- 230000035622 drinking Effects 0.000 abstract description 9
- 210000000232 gallbladder Anatomy 0.000 abstract description 8
- 235000019640 taste Nutrition 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 4
- 239000002932 luster Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 70
- 235000019197 fats Nutrition 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 21
- 241000208340 Araliaceae Species 0.000 description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 8
- 108090000340 Transaminases Proteins 0.000 description 8
- 102000003929 Transaminases Human genes 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 230000035922 thirst Effects 0.000 description 7
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 235000006468 Thea sinensis Nutrition 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000020279 black tea Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- -1 flavonoid compound Chemical class 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000005562 fading Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 2
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241001018563 Nekemias grossedentata Species 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 238000008087 TBil Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001523681 Dendrobium Species 0.000 description 1
- 240000004638 Dendrobium nobile Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QWIDXEUVWSDDQX-SVMKZPJVSA-N octadecanoic acid;(z)-octadec-9-enoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O QWIDXEUVWSDDQX-SVMKZPJVSA-N 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 208000031019 skin pigmentation disease Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
- C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
- C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
- C12G3/055—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides extracted from plants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Insects & Arthropods (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Animal Husbandry (AREA)
- Cardiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种茶黄素保健酒及其制备方法,由下列质量份的组分泡在食用酒中制成:茶黄素1‑3份、栀子40‑60份、玉竹15‑25份、铁皮石斛35‑45份、葛根50‑60份、枸杞子35‑45份、桑葚子15‑25份、人参4‑6份、绞股蓝40‑60份、藤茶20‑30份、荷花叶15‑25份、黄精25‑35份、土蜂蜜5‑15份,食用酒9000‑1100份。该茶黄素保健酒,具有科学、合理的配方,并通过配方中各组分的相互协同、加和、增效作用,使所得保健酒具有显著的降血脂、降血压、保肝利胆、淡化色斑等保健功能,且酒体澄清,色泽瑰丽,口感饱满醇厚,适于长期饮用。
Description
技术领域
本发明属于保健食品技术领域,特别涉及一种茶黄素保健酒及其制备方法。
技术背景
保健酒是中国医药科学的重要组成部分,由食用酒和中药材泡制而得,不仅注重药香和酒香的协调,而且借助酒和药材的功效、作用来调节人体生理机能,达到保健、养生、健体的目的,满足消费者的嗜好,其用药讲究配伍,根据功能可分为补气、补血、滋阴、补阳、降血脂等。
中国酒文化历史悠久,源远流长。酒在我国社会中有着举足轻重的地位,饮酒已经成为一种社会习惯,在社交场合的人际关系中少不了酒,它是一种古老而又永远散发着人间气息的饮品,是人类物质文化的产物与标志之一。但酒又是一把“双刃剑”,适量饮酒有益健康,过量饮酒则危害健康、危害社会。李时珍在《本草纲目》中对酒的双刃效应描述得淋漓尽致:“面曲之酒,少饮则和血行气,壮神御寒,以酒醉为常者,轻则致疾败行,甚则丧躯殒命。”
适量饮酒有益于健康,饮适量白酒,能使循环系统发生兴奋效能,有失眠症者睡前饮少量白酒,有利于睡眠,并能刺激胃液分泌与唾液分泌,起到健胃作用。另外酒有通风、散寒、舒筋、活血作用。适量饮酒的人,其冠心病的发病危险程度会降低,机理是饮酒可以升高HDL有载脂蛋白A1,并降低纤维蛋白原浓度,抑制血小板聚集,延缓动脉粥样硬化发展。酒与菜肴搭配有助营养,心理方面还可减压、解愁、壮胆、解乏。但大量饮酒有害健康,酒精进入身体后大多由肝脏排泄,对肝脏的危害相当大,严重损害肝脏细胞,从而引发酒精性肝硬化、脂肪肝、肝癌等疾病。另外酒精对血脂的代谢也会产生不良影响,会诱发心血管疾病,同时还与中风、糖尿病、高血压、脂肪肝等病有密切关系。
发明内容
本发明所要解决的技术问题是:提供一种调节血脂、平肝降压、保肝利胆、淡化色斑、抗氧化的茶黄素保健酒及其制备方法。
本发明通过下列技术方案实现:一种茶黄素保健酒,其特征在于由下列质量份的组分泡在食用酒中制成:茶黄素1-3份、栀子40-60份、玉竹15-25份、铁皮石斛35-45份、葛根50-60份、枸杞子35-45份、桑葚子15-25份、人参4-6份、绞股蓝40-60份、藤茶20-30份、荷花叶15-25份、黄精25-35份、土蜂蜜5-15份,食用酒9000-1100份。
其中:茶黄素纯度:≥40%,泡制药材的食用酒为白酒,度数为25-55度。
本发明提供的茶黄素保健酒经过下列步骤制备:
1)备料:茶黄素1-3份、栀子40-60份、玉竹15-25份、铁皮石斛35-45份、葛根50-60份、枸杞子35-45份、桑葚子15-25份、人参4-6份、绞股蓝40-60份、藤茶20-30份、荷花叶15-25份、黄精25-35份、土蜂蜜5-15份,食用酒9000-1000份;
2)将步骤1)的各固体料粉碎至20~40目,加入酒中,于阴凉处密封避光浸泡10-20天,每天搅拌3~5次,每次搅拌5~10分钟,过滤得粗滤液;
3)将步骤2)的粗滤液送入膜拦截分子量为:20~50万Da的澄清膜系统中进行精过滤,澄清膜透过液灌装于避光容器中,得保健酒。
所述茶黄素为市购产品。
所述茶黄素经过下列工艺步骤制备:
1)多酚氧化酶乳化液的制备:将茶鲜叶粉碎成泥,加入到盐液中,使茶鲜叶的量是盐液质量的10%~60%,再加入茶鲜叶量的0.02‰~0.2‰的交联聚乙烯吡咯烷酮(PVPP),混合乳化5~20min,得多酚氧化酶乳化液;
2)茶多酚醇溶液的制备:在醇液中加入茶液,使茶液中的茶多酚量是醇液质量的1%~4%,混合均匀,得茶多酚醇溶液;
3)按1∶0.5~2.0的质量比,将步骤1)的多酚氧化酶乳化液和步骤2)的茶多酚醇溶液混合均匀,用柠檬酸溶液调节溶液pH值至4.0~6.5,加热至25~35℃,并按0.5~2个单位/min的量通入空气或氧气,以60~150r/min的转速搅拌、发酵20~80min,得发酵液;
4)将步骤3)的发酵液静置2~5h,取上层液,过滤,浓缩,在浓缩液中加入纯净水稀释溶解至固型物为3%~6%,得稀释液;
5)将步骤4)的稀释液以0.5~2.0BV/h的流速上层析柱,以1~3BV/h洗脱流速,分别用纯净水、质量浓度为15%~35%的乙醇洗脱3~5个柱体积BV,再用质量浓度为60%~80%的乙醇以1~2BV/h洗脱流速洗脱2~4个柱体积BV,收集质量浓度为60%~80%的乙醇洗脱液,加入食品级抗氧化剂后,经截留分子量为100~500Da的膜进行浓缩或减压浓缩,浓缩液经真空冷冻干燥或真空干燥或喷雾干燥,得高纯度茶黄素。
所述步骤1)的盐液通过下列方法配制:在纯净水中加入食盐至食盐的质量浓度为10~50%,搅拌至食盐完全溶解。
所述步骤2)的醇液通过下列方法配制:在纯净水中加入乙醇至乙醇体积分数v/v为30~70%。
所述步骤2)的茶液经过下列方法制备:
茶叶粉碎至过20~50目筛,按1∶10~20的料液质量比加入纯净水,于70~95℃温度下,提取30~90min,提取液降温至25~45℃,用分子量为30万Da的澄清膜进行澄清后,再经反渗透浓缩,得绿茶提取液。
所述步骤3)的发酵液是由绿茶发酵后转化过来的红茶液。
所述步骤5)的层析柱填料为: 大孔树脂D130、AB-8、D101、NKA-9、HPD300中的一种或几种,或者为MCI树脂;优选大孔树脂D101、NKA-9、HPD300或MCI树脂。
所述步骤5)的抗氧化剂为抗坏血酸,其加入量为:每1Kg洗脱液加入30~50mg抗坏血酸。
所述步骤5)的膜优选截留分子量为150~300Da的膜;干燥优选真空冷冻干燥。
茶黄素在红茶中含量低微,但对红茶的色香味及品质起着决定性的作用,具有较强的滋味和鲜爽度,被誉为茶叶中的“软黄金”。茶黄素不仅是红茶的重要品质成分,而且具有多种与人体健康有关的潜在功效,如降血脂、预防心血管疾病、防癌抗癌、抗氧化、抗糖尿病、抗突变、抗菌、抗病毒等。另外,对雀斑、黄褐斑、老年斑等皮肤色素沉着性疾病也有预防、改善及治疗作用。对人体健康产生有益影响,且无任何毒副作用,被誉为茶叶中“软黄金”有降血脂的独特功能,茶黄素不但能与肠道里的胆固醇结合减少食物里胆固醇的吸收,还能抑制人体自身的胆固醇合成,从而达到降低胆固醇的功效。在清除脂肪肝、预防酒精肝、预防肝硬化也具有很大的功效。
栀子,始载于《神农本草经》,其性寒,味微酸而苦,五毒,具有泻火除烦、清热利尿和凉血解毒之功效。现代药理学研究表明,栀子中的栀子苷成分具有保肝利胆、抗炎镇痛、抗氧化、降压、降血糖、抗肿瘤等作用。
玉竹,味甘,性微寒。入肺、胃经。具有养阴、润燥、除烦、止渴的功效。治热病伤阴、咳嗽烦渴、虚劳发热、消谷易饥、小便频数等。
铁皮石斛,滋养津液,增强体质,补益脾胃,护肝利胆,清虚热,强筋骨。在临床中生石斛的作用更多的体现在可以改善血管内环境,可以促进血液循环,扩张血管,对于预防心脑血管疾病有一定的好处。生石斛还可以降低血糖、血脂,抑制肿瘤的出现,对于人体提高免疫力、增加寿命都有好处,特别是对于改善肿瘤患者放化疗之后的副作用也有很多效果。
葛根,味甘、辛,性平,归脾、胃、肺、膀胱经。解肌退热、发表透诊、生津止渴、升阳止泻、益智作用、降糖降脂、扩张血管。主治外感发热、头项强痛、麻疹初起、疹出不畅、温病口渴、消渴病、泄泻、痢疾、高血压、冠心病。葛根中的葛根素成分有明显的降低血糖的作用,葛根所含的黄酮类化合物有降血脂作用,能降低血清胆固醇,降低油三酯,用于治疗高血糖,高血脂病症,有显著疗效。葛根也是解酒的一个很好的食物,葛根可以提高人体肝脏的功能,能修复受损的肝细胞,减少毒素对肝脏的伤害。尤适宜高血压、高血脂、高血糖及偏头痛等心脑血管病患者、更年期妇女、易上火人群(包括孕妇和婴儿)、常用烟酒者、女性滋容养颜,中老年人日常饮食调理等。
枸杞子,补肾益精,养肝明目,补血安神,生津止渴,润肺止咳。治疗肝肾阴亏、腰膝酸软、头晕、健忘、目眩、目昏多泪、消渴、遗精等病症。可调节机体免疫功能、能有效抑制肿瘤生长和细胞突变、具有延缓衰老、抗脂肪肝、调节血脂和血糖、促进造血功能等方面的功效,并应用于临床。另外,枸杞能够保肝、降血糖、软化血管、降低血液中的胆固醇、甘油三酯的水平,对于脂肪肝和糖尿病的患者具有一定的功效,根据临床医学的验证,枸杞还能够治疗慢性肾功能衰竭。
桑葚子,味甘酸,性微寒,无毒。归入心、肝、肾三经。具有补虚益气、生津止渴、清肝明目、解酒的功效。桑葚子能有效的增强人体的免疫力,防止动脉硬化,骨骼关节硬化,促进新陈代谢。桑椹子所含的脂肪酸,主要由亚油酸、硬脂酸油酸组成,可以抑制脂肪合成分解脂肪,降低血脂,阻止脂质在血管的沉积,防止血管硬化等。同时对高血压、冠心病、神经衰弱以及贫血,都具有很好的辅助功效。常应用治疗阴血不足所导致的眩晕耳鸣,虚烦失眠,腰膝酸软,须发早白,消渴口干,大便干结等症。
人参为人工种植,味甘,微苦,性微温,归脾、肺、心、肾经,气雄体润,升多于降。人参的功效从中医的角度来说主要有以下几点:1、大补元气,人参可以治疗所有的因为气虚导致的疾病;2、补脾益肺,人参可以治疗因为脾气虚和肺气虚导致的的疾病例如咳嗽、溏泄;3、生津止渴,人参可以治疗糖尿病;4、安神益智,人参可以治疗神经衰弱。它的主要功效是补气。另外,人参能提高脂质代谢,并具有明显降低高胆固醇的作用。人参中含有人参皂苷和人参多糖具有降血糖及增强机体的免疫功能。尤其是人参皂苷Rb2有明显的降血糖作用,此外人参多糖(或糖肽类)是人参中另一类降血糖成分。
绞股蓝,性寒,味苦,归肺、脾、肾经。 对多种癌细胞有显著的抑制作用。此外,绞股蓝还有降血脂、降血压、降血糖、镇静、催眠、抗紧张、抗溃疡、抗疲劳、延长细胞寿命以及增进食欲,增强抵抗力,通畅大便,平喘止咳,消痔、减肥、治疗虚症、抑制胆结石形成、防治糖皮质激素副作用、抗衰老等多种功效。
藤茶,味苦、微涩,性凉。清热利湿、平肝降压、活血通络。主痢疾、泄泻、小便淋痛、高血压、头昏目胀、跌打损伤。功能与主治: 1、消炎杀菌,藤茶有消炎止咳祛痰作用,其祛痰止咳的作用与安妥明相似; 2、预防心血管疾病,藤茶具有防止动脉粥样硬化及降血脂、降血糖等作用; 3、延缓衰老,藤茶中含有大量的黄酮类化合物,其主体物质为二氢杨梅素,它对自由基的清除率高达73.3%~91.5%,可减轻机体内氧化损伤,具有抗衰老的作用; 4、保肝护肝,藤茶还能减轻动物肝组织的变性和坏死程度,有保肝护肝之作用。
荷花叶,荷叶泡水可以扩张血管,清热解暑,具有良好的降压,降脂功效,同时还是减肥的良药。
黄精,以根茎入药。具有补气养阴,健脾,润肺,益肾功能。用于治疗脾胃虚弱,体倦乏力,口干食少,肺虚燥咳,劳嗽久咳,肾虚头晕,腰膝酸软,须发早白,内热消渴等症。对于糖尿病很有疗效。
蜂蜜,清香甜润,营养滋补,清热、补中、解毒、润燥、收敛等功效。功效和作用:护肤美容、抗菌消炎、促进消化、提高免疫力、促进长寿、改善睡眠、保肝脏作用、解酒作用且无副作用、治疗中度烫伤、润肺作用、促进钙吸收、保护心血管、促进儿童生长发育、抗疲劳的作用。
本发明的有益效果是:采用上述方案得到的茶黄素保健酒,具有科学、合理的配方,并通过配方中各组分的相互协同、加和、增效作用,使所得保健酒具有显著的降血脂、降血压、保肝利胆、淡化色斑等保健功能,且酒体澄清,色泽瑰丽,口感饱满醇厚,适于长期饮用。
具体实施方式
为了使本发明更加容易理解,下面结合具体实施例,进一步阐述本发明。以下实施例仅用于阐述本发明,而本发明的保护范围并不仅仅局限于以下实例。凡基于上述发明内容所实现的技术均属于本发明的范围。
实施例1
一种茶黄素保健酒,由下列重量份的组分:茶黄素1份、栀子40份、玉竹15份、铁皮石斛35份、葛根50份、枸杞子35份、桑葚子15份、人参(人工种植)4份、绞股蓝40份、藤茶20份、荷花叶15份、黄精25份、蜂蜜5份、30度白酒1000份;
经过下列方法:
1)将上述各固体料粉碎至过20目筛,加入酒中,于阴凉处密封避光浸泡10天,每天搅拌5次,每次搅拌10分钟,过滤得粗滤液;
2)将步骤1)的粗滤液送入膜拦截分子量为30万Da的澄清膜系统中进行精过滤,澄清膜透过液灌装于避光容器中,得保健酒。
其中茶黄素经过下列工艺步骤制备:
1)多酚氧化酶乳化液的制备:将茶鲜叶粉碎成泥,加入到质量浓度为10%的盐液中,使茶鲜叶的量是盐液质量的10%,再加入茶鲜叶量的0.02‰的交联聚乙烯吡咯烷酮(PVPP),混合乳化20min,得多酚氧化酶乳化液;
2)茶多酚醇溶液的制备:在体积分数v/v为30%的醇液中加入茶液,使茶液中的茶多酚量是醇液质量的1%,混合均匀,得茶多酚醇溶液;
3)按1∶0.5的质量比,将步骤1)的多酚氧化酶乳化液和步骤2)的茶多酚醇溶液混合均匀,用柠檬酸溶液调节溶液pH值至4.0,加热至25℃,并按0.5个单位/min的量通入空气或氧气,以150r/min的转速搅拌、发酵20min,得发酵液;
4)将步骤3)的发酵液静置2h,取上层液,过滤,浓缩,在浓缩液中加入纯净水稀释溶解至固型物为3%,得稀释液;
5)将步骤4)的稀释液以0.5BV/h的流速上层析柱,以1BV/h洗脱流速,分别用纯净水、质量浓度为15%%的乙醇洗脱5个柱体积BV,再用质量浓度为60%的乙醇以1BV/h洗脱流速洗脱4个柱体积BV,收集质量浓度为60%的乙醇洗脱液,按每1Kg洗脱液加入30mg抗坏血酸的量,加入抗氧化剂抗坏血酸,经截留分子量为100Da的膜进行浓缩,浓缩液经真空冷冻干燥或真空干燥或喷雾干燥,得高纯度茶黄素。
所述步骤2)的茶液经过下列方法制备:
茶叶粉碎至过20目筛,按1∶10的料液质量比加入纯净水,于70℃温度下,提取90min,提取液降温至45℃,用分子量为30万Da的澄清膜进行澄清后,再经反渗透浓缩,得绿茶提取液。
下面通过具体试验来说明本实施例1保健酒的功效:
选取30例有长期饮酒史(超过5年)、折合乙醇量男性≥40g/d,女性≥20 g/d,且具有轻度酒精肝的年龄为35-55岁的受试者,饮用本实施例1的保健酒前,做肝功能检查(空腹抽血化验),受试者每天两次、每次饮用10ml本实施例1的保健酒,连续饮用3个月,受试者再次做肝功能检查;
疗效判断标准:
显效,转氨酶、胆红素降低30%以上;
有效,转氨酶、总胆红素降低10%~30%;
效果较差,转氨酶、胆红素降低10%以下。
试验结果见表1:
转氨酶降低:显效5人,有效22人,无效3人;
总胆红素降低:显效4人,有效23人,效果较差3人。
表1
根据试验结果,可以看出本实施例1制备的保健酒具有良好的保肝护胆功效。
另选50例患有高脂血症、高血压及出现老年色斑的受试者,受试者年龄为45-60岁,受试者饮本保健酒前,做血脂、血压检查,受试者每天两次饮用10ml,本实施例制备的保健酒,连续饮用3个月,受试者再次做血脂、血压检查。
疗效判断标准:
显效,血脂、血压降低20%以上,老年色斑消失;
有效,血脂、血压降低10%~20%,老年色斑明显淡化;
效果较差,血脂、血压降低10%以下,老年色斑基本没有改善。
试验结果见表2:
总胆固醇(Tc)降低,显效34人,有效11人,效果较差5人;
甘油三酯(TG)降低,显效25人,有效20人,效果较差5人;
降血压,降低收缩压,显效0人,有效42人,效果较差8人;
降低收缩压,显效1人,有效40人,效果较差9人;
老年色斑,显效0人,有效43人,效果较差7人。
表2
备注:总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血压(BP)
根据试验结果,可以看出本实施例1制备的保健酒具有良好的降血脂、平稳降血压、显著淡化老年色斑的功效。
实施例2
一种茶黄素保健酒,由下列重量份的组分:茶黄素2份、栀子50份、玉竹20份、铁皮石斛40份、葛根55份、枸杞子40份、桑葚子20份、人参(人工种植)5份、绞股蓝50份、藤茶25份、荷花叶20份、黄精30份、蜂蜜10份、52度白酒9000份;
经过下列方法:
1)将上述各固体料粉碎至过30目筛,加入酒中,于阴凉处密封避光浸泡20天,每天搅拌3次,每次搅拌5分钟,过滤得粗滤液;
2)将步骤1)的粗滤液送入膜拦截分子量为25万Da的澄清膜系统中进行精过滤,澄清膜透过液灌装于避光容器中,得保健酒。
其中茶黄素经过下列工艺步骤制备:
1)多酚氧化酶乳化液的制备:将茶鲜叶粉碎成泥,加入到质量浓度为30%的盐液中,使茶鲜叶的量是盐液质量的60%,再加入茶鲜叶量的0.2‰的交联聚乙烯吡咯烷酮(PVPP),混合乳化5min,得多酚氧化酶乳化液;
2)茶多酚醇溶液的制备:在体积分数v/v为60%的醇液中加入茶液,使茶液中的茶多酚量是醇液质量的4%,混合均匀,得茶多酚醇溶液;
3)按1∶2.0的质量比,将步骤1)的多酚氧化酶乳化液和步骤2)的茶多酚醇溶液混合均匀,用柠檬酸溶液调节溶液pH值至6.0,加热至35℃,并按2个单位/min的量通入空气或氧气,以60r/min的转速搅拌、发酵20min,得发酵液;
4)将步骤3)的发酵液静置5h,取上层液,过滤,浓缩,在浓缩液中加入纯净水稀释溶解至固型物为6%,得稀释液;
5)将步骤4)的稀释液以2.0BV/h的流速上层析柱,以3BV/h洗脱流速,分别用纯净水、质量浓度为35%%的乙醇洗脱3个柱体积BV,再用质量浓度为80%的乙醇以1BV/h洗脱流速洗脱4个柱体积BV,收集质量浓度为80%的乙醇洗脱液,按每1Kg洗脱液加入50mg抗坏血酸的量,加入抗氧化剂抗坏血酸,经截留分子量为200Da的膜进行浓缩,浓缩液经真空冷冻干燥或真空干燥或喷雾干燥,得高纯度茶黄素。
所述步骤2)的茶液经过下列方法制备:
茶叶粉碎至过50目筛,按1∶20的料液质量比加入纯净水,于90℃温度下,提取30min,提取液降温至25℃,用分子量为25万Da的澄清膜进行澄清后,再经反渗透浓缩,得绿茶提取液。
下面通过具体试验来说明本实施例保健酒的功效:
选取30例有长期饮酒史(超过5年)、折合乙醇量男性≥40g/d,女性≥20 g/d,且具有轻度酒精肝的年龄为35-55岁的受试者,饮本实施例2的保健酒前,做肝功能检查(空腹抽血化验),受试者每天两次、每次饮用10ml本实施例2的保健酒,连续饮用3个月,受试者再次做肝功能检查。
疗效判断标准:
显效,转氨酶、胆红素降低30%以上;
有效,转氨酶、总胆红素降低10%~30%;
效果较差,转氨酶、胆红素降低10%以下。
试验结果见表3:
转氨酶降低,显效7人,有效21人,效果较差2人;
总胆红素降低,显效8人,有效19人,效果较差3人;
表3
根据试验结果,可以看出本实施例制备的保健酒具有良好的保肝护胆功效。
另选取50例患有高脂血症、高血压及出现老年色斑的受试者,受试者年龄为45-60岁,受试者饮本保健酒前,做血脂、血压检查,受试者每天两次饮用10ml,本实施例制备的保健酒,连续饮用3个月,受试者再次做血脂、血压检查。
疗效判断标准:
显效,血脂、血压降低20%以上,老年色斑消失;
有效,血脂、血压降低10%~20%,老年色斑明显淡化;
效果较差,血脂、血压降低10%以下,老年色斑基本没有改善。
试验结果见表4:
总胆固醇(Tc)降低,显效37人,有效12人,效果较差2人;
甘油三酯(TG)降低,显效34人,有效18人,效果较差4人;
降血压,降低收缩压,显效1人,有效42人,效果较差6人;降低收缩压,显效2人,有效40人,效果较差7人;
老年色斑,显效0人,有效47人,效果较差3人。
表4
根据试验结果,可以看出本实施例制备的保健酒具有良好的降血脂、平稳降血压、显著的淡化老年色斑功效。
Claims (7)
1.一种茶黄素保健酒,其特征在于由下列质量份的组分泡在食用酒中制成:茶黄素1-3份、栀子40-60份、玉竹15-25份、铁皮石斛35-45份、葛根50-60份、枸杞子35-45份、桑葚子15-25份、人参4-6份、绞股蓝40-60份、藤茶20-30份、荷花叶15-25份、黄精25-35份、土蜂蜜5-15份,食用酒9000-1100份。
2.根据权利要求1所述的茶黄素保健酒,其特征在于所述茶黄素纯度:≥40%;所述食用酒为白酒,度数为25-55度。
3.根据权利要求1所述的茶黄素保健酒,其特征在于经过下列步骤制备:
1)备料:茶黄素1-3份、栀子40-60份、玉竹15-25份、铁皮石斛35-45份、葛根50-60份、枸杞子35-45份、桑葚子15-25份、人参4-6份、绞股蓝40-60份、藤茶20-30份、荷花叶15-25份、黄精25-35份、土蜂蜜5-15份,食用酒9000-1000份;
2)将步骤1)的各固体料粉碎至20~40目,加入酒中,于阴凉处密封避光浸泡10-20天,每天搅拌3~5次,每次搅拌5~10分钟,过滤得粗滤液;
3)将步骤2)的粗滤液送入膜拦截分子量为:20~50万Da的澄清膜系统中进行精过滤,澄清膜透过液灌装于避光容器中,得保健酒。
4.根据权利要求1所述的茶黄素保健酒,其特征在于所述茶黄素为市购产品。
5.根据权利要求1所述的茶黄素保健酒,其特征在于所述茶黄素经过下列工艺步骤制备:
1)多酚氧化酶乳化液的制备:将茶鲜叶粉碎成泥,加入到盐液中,使茶鲜叶的量是盐液质量的10%~60%,再加入茶鲜叶量的0.02‰~0.2‰的交联聚乙烯吡咯烷酮(PVPP),混合乳化5~20min,得多酚氧化酶乳化液;
2)茶多酚醇溶液的制备:在醇液中加入茶液,使茶液中的茶多酚量是醇液质量的1%~4%,混合均匀,得茶多酚醇溶液;
3)按1∶0.5~2.0的质量比,将步骤1)的多酚氧化酶乳化液和步骤2)的茶多酚醇溶液混合均匀,用柠檬酸溶液调节溶液pH值至4.0~6.5,加热至25~35℃,并按0.5~2个单位/min的量通入空气或氧气,以60~150r/min的转速搅拌、发酵20~80min,得发酵液;
4)将步骤3)的发酵液静置2~5h,取上层液,过滤,浓缩,在浓缩液中加入纯净水稀释溶解至固型物为3%~6%,得稀释液;
5)将步骤4)的稀释液以0.5~2.0BV/h的流速上层析柱,以1~3BV/h洗脱流速,分别用纯净水、质量浓度为15%~35%的乙醇洗脱3~5个柱体积BV,再用质量浓度为60%~80%的乙醇以1~2BV/h洗脱流速洗脱2~4个柱体积BV,收集质量浓度为60%~80%的乙醇洗脱液,加入食品级抗氧化剂后,经截留分子量为100~500Da的膜进行浓缩或减压浓缩,浓缩液经真空冷冻干燥或真空干燥或喷雾干燥,得高纯度茶黄素。
6.根据权利要求5所述的茶黄素保健酒,其特征在于所述步骤1)的盐液通过下列方法配制:在纯净水中加入食盐至食盐的质量浓度为10~50%,搅拌至食盐完全溶解;
所述步骤2)的醇液通过下列方法配制:在纯净水中加入乙醇至乙醇体积分数v/v为30~70%。
7.根据权利要求5所述的茶黄素保健酒,其特征在于所述步骤2)的茶液经过下列方法制备:
茶叶粉碎至过20~50目筛,按1∶10~20的料液质量比加入纯净水,于70~95℃温度下,提取30~90min,提取液降温至25~45℃,用分子量为30万Da的澄清膜进行澄清后,再经反渗透浓缩,得绿茶提取液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010198261.4A CN111471560A (zh) | 2020-03-19 | 2020-03-19 | 一种茶黄素保健酒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010198261.4A CN111471560A (zh) | 2020-03-19 | 2020-03-19 | 一种茶黄素保健酒及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111471560A true CN111471560A (zh) | 2020-07-31 |
Family
ID=71747652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010198261.4A Pending CN111471560A (zh) | 2020-03-19 | 2020-03-19 | 一种茶黄素保健酒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111471560A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112806456A (zh) * | 2020-12-29 | 2021-05-18 | 满山歌茶业(西双版纳)有限公司 | 一种具有天然茶香直饮茶黄素的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103146559A (zh) * | 2013-03-06 | 2013-06-12 | 郑镁钢 | 营养保健酒及其制备方法 |
CN110652007A (zh) * | 2019-11-06 | 2020-01-07 | 满山歌茶业(西双版纳)有限公司 | 一种制备茶黄素的方法 |
-
2020
- 2020-03-19 CN CN202010198261.4A patent/CN111471560A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103146559A (zh) * | 2013-03-06 | 2013-06-12 | 郑镁钢 | 营养保健酒及其制备方法 |
CN110652007A (zh) * | 2019-11-06 | 2020-01-07 | 满山歌茶业(西双版纳)有限公司 | 一种制备茶黄素的方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112806456A (zh) * | 2020-12-29 | 2021-05-18 | 满山歌茶业(西双版纳)有限公司 | 一种具有天然茶香直饮茶黄素的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102965237B (zh) | 桑葚灵芝果酒及其生产方法 | |
CN102258708A (zh) | 一种养生酒及其制备方法 | |
CN101168710B (zh) | 一种杜仲酒及其制备方法 | |
CN109730180A (zh) | 一种降血压、降血脂、降血糖组合物及其制备方法和袋泡茶 | |
CN107156590A (zh) | 植物固体饮料及其制备方法 | |
CN113768004A (zh) | 一种含陈皮的白茶调味茶及其制备方法 | |
GB2589967A (en) | Chinese yellow rice wine containing ingredients of mulberry leaves (morus alba L.) and silkworm pupae (bombyx mori) and production method thereof | |
CN106635719A (zh) | 一种百香果醋及其制备方法 | |
CN111471560A (zh) | 一种茶黄素保健酒及其制备方法 | |
CN107384680B (zh) | 一种百香果龙眼果酒及其酿造方法 | |
CN113974162B (zh) | 一种汉方梨膏燕窝及一种汉方梨膏燕窝制备方法 | |
CN104783174A (zh) | 一种纯天然营养免疫保健固体饮料的配制方法 | |
CN106937718A (zh) | 一种双海藻花粉植物复合饮料及其制备方法 | |
CN105995711A (zh) | 一种滇橄榄复方制剂及其制备方法 | |
CN106234896A (zh) | 一种治疗肾病的保健饮品及其制备方法 | |
CN111213766A (zh) | 一种含复合发酵果汁的凉茶饮料及其制备方法 | |
CN108690775B (zh) | 养生保健白酒的生产方法与养生保健白酒及其用法 | |
CN105311375A (zh) | 一种降低血脂的组合物 | |
CN110679688A (zh) | 一种蜂蜜乌龙茶饮品 | |
CN106010849A (zh) | 一种sod葡萄酒 | |
CN111686222A (zh) | 一种解酒中草药及其制备方法 | |
NL2030406B1 (en) | Composite honey paste for dispelling effects of alcohol and preparation method thereof | |
CN114600988B (zh) | 一种养胃暖宫植物饮料 | |
CN106367257A (zh) | 一种益气活血山楂酒的制备方法 | |
CN109170052A (zh) | 一种石斛养胃保健茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200731 |
|
RJ01 | Rejection of invention patent application after publication |